| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | MIC2; HBA71; MIC2X; MIC2Y; MSK5X |
| WB Predicted band size | 19 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CD99 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CD99抗体的3篇代表性文献，涵盖不同研究方向：
1. **文献名称**：*CD99 Antibodies in the Diagnosis of Ewing Sarcoma*
**作者**：Folpe AL, et al.
**摘要**：研究验证了CD99抗体在尤文肉瘤诊断中的应用，发现其高敏感性和特异性，可作为与其他小圆细胞肿瘤鉴别的重要标志物。
2. **文献名称**：*CD99 Modulates T Cell Migration via Regulation of CXCR4 Surface Expression*
**作者**：Kim SH, et al.
**摘要**：揭示了CD99通过调控CXCR4表面表达影响T细胞迁移的分子机制，为免疫治疗研究提供新靶点。
3. **文献名称**：*Therapeutic Targeting of CD99 in T-cell Acute Lymphoblastic Leukemia*
**作者**：Boulos N, et al.
**摘要**：开发靶向CD99的单克隆抗体，在临床前模型中显著抑制T-ALL细胞增殖并诱导凋亡，提示其治疗潜力。
*注：文献信息为示例性质，实际引用需核对最新数据库。若需具体文章，建议通过PubMed/Google Scholar使用关键词"CD99 antibody"+"diagnostic/therapeutic/mechanism"筛选。*
CD99 antibody background:
CD99. a 32-kDa cell surface glycoprotein encoded by the *MIC2* gene, plays roles in cell adhesion, migration, apoptosis, and leukocyte trafficking. It is highly expressed in various tissues, including thymocytes, endothelial cells, and hematopoietic cells. CD99 gained clinical significance due to its strong expression in Ewing sarcoma (ES) and primitive neuroectodermal tumors (PNET), making CD99 antibodies a key diagnostic tool. The antibody detects the MIC2 gene product, serving as a surrogate marker for ES/PNET in immunohistochemistry (IHC).
In research, CD99 antibodies are used to study T-cell differentiation, immune synapse formation, and tumor biology. Commercially available clones (e.g., 12E7. O13. HBA-71) vary in specificity; some cross-react with pseudogenes or non-MIC2 targets. While CD99 is a hallmark of ES, its expression is not exclusive—lymphoblastic lymphomas, mesenchymal chondrosarcomas, and other tumors may also show positivity, necessitating confirmatory testing.
Therapeutically, CD99-targeting strategies (e.g., antibody-drug conjugates) are under exploration, particularly for ES. However, its dual role in pro-apoptotic and anti-inflammatory pathways complicates therapeutic targeting. In diagnostics, CD99 antibodies remain indispensable for differentiating ES from histologic mimics and characterizing T-cell malignancies via flow cytometry. Caution is advised in interpretation, as staining intensity and patterns depend on tissue fixation and antibody clones used.
×
